HealthCor Management’s Celldex Therapeutics CLDX Stock Holding History

HealthCor Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-10,907	Closed	-$2.99M	–	68
2014 Q4	$2.99M	Buy	+10,907	New	+$2.71M	0.17%	46
2013 Q4	–	Sell	-1,753	Closed	-$932K	–	54
2013 Q3	$932K	Sell	1,753 -94,914	-98%	-$32.5M	0.05%	58
2013 Q2	$22.6M	Buy	+96,667	New	+$19M	1.37%	26

Other funds holding CLDX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

HealthCor Management's CLDX Position: Q1 2015 in Review

HealthCor Management sold out of Celldex Therapeutics (CLDX) in Q1 2015, closing a stake of 10,907 shares — an estimated $2.99M sold.

HealthCor Management first reported a position in CLDX in Q2 2013 and held it in 3 quarters. The position peaked at $22.6M in Q2 2013. 193 funds tracked by Wall St. Rank hold CLDX as of Q1 2015.

HealthCor Management reported no remaining Celldex Therapeutics position as of Q1 2015 after selling out during the quarter.
HealthCor Management sold 10,907 Celldex Therapeutics shares in Q1 2015, an estimated $2.99M.
HealthCor Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 3 quarters.
HealthCor Management's Celldex Therapeutics position peaked at $22.6M in Q2 2013.
193 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2015.

Based on HealthCor Management's 13F filing for Q1 2015, filed 15 May 2015.